The SAPPHIRE study is a randomized.

The results of a earlier randomized, active-controlled Phase IIb study show that the novel, targeted therapy retains significant promise. Currently recruiting study centers will be released on.. Antisense Pharma’s SAPPHIRE Phase III trial evaluating trabedersen approved by Health Canada Study to examine trabedersen vs. Current regular chemotherapy in individuals with recurrent or refractory anaplastic astrocytoma The biopharmaceutical firm Antisense Pharma GmbH provides announced today that it has received the acceptance by Health Canada for its pivotal Stage III clinical trial SAPPHIRE in patients with recurrent or refractory anaplastic astrocytoma.Furthermore to treating RA, Professor Mackay believes their therapeutic may be used for psoriasis, sepsis, coronary attack and transplant individuals. Professor John Shine FAA AO, Executive Director of the Garvan Institute says: ‘It is necessary to utilize businesses if we are to carefully turn scientific discoveries into actual individual benefits. The Garvan’s dedication to taking our analysis from bench to bedside can be evidenced by our expenditure in businesses such as for example G2 and encouraging our senior researchers to take part in the commercialisation of analysis’. The Novo Nordisk licensing contract has a potential worth of over US$100 million , rendering it among the largest licensing agreements ever guaranteed by an Australian biotechnology firm.

Other Posts From Category "hepatology":

Related Posts